查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1771539

全球癌症伴隨診斷市場：市場規模、佔有率、趨勢分析（按產品/服務、技術、疾病類型、最終用途和地區）、細分市場預測（2025-2030 年）

Oncology Companion Diagnostic Market Size, Share & Trends Analysis Report By Product & Service, By Technology (PCR, IHC, NGS), By Disease Type (Breast Cancer), By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

癌症伴隨診斷市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球癌症伴隨診斷市場規模預計到2030年將達到83.8億美元，2025年至2030年期間的複合年成長率為9.02%。

由於伴隨診斷能夠提供更多關鍵基因組資訊，從而幫助患者做出明智的決策並為患者設計標靶治療方法，因此對全面基因組檢測和癌症伴隨診斷的需求正在增加。

Gleevec/Glivec（Imatinib）和Herceptin（曲妥珠單抗）等需要在處方前進行伴隨診斷 (CDx) 檢測的藥物的上市，增加了癌症伴隨診斷的收益。由於臨床試驗中有大量與伴隨診斷相關的癌症藥物，預計未來將持續下去。除了作為治療的專屬或綜合檢測外，伴隨診斷還在臨床試驗參與者的選擇中發揮關鍵作用，因為如果患者俱有生物標記靶點，候選藥物更有可能表現出更高的反應率。

與CDx應用相關的經濟獎勵正在鼓勵藥物開發人員將藥物與診斷測試配對。然而，診斷公司面臨著來自支付方/醫療保健提供者和藥品製造商的相互衝突的需求。此外，監管機構對協調診斷和藥物開發時間表有著嚴格的政策。因此，預計診斷公司將擴大其CDx開發的範圍，而不是專注於將單一診斷與特定藥物配對。

癌症伴隨診斷市場報告重點

  • 在個人化醫療進步和癌症發病率不斷上升的推動下，產品領域預計將在 2024 年佔據市場主導地位，佔有率達到 66.14%，而服務領域預計將在預測期內實現最快的複合年成長率。
  • 預計聚合酵素鏈鎖反應(PCR) 領域將在 2024 年佔據市場主導地位，佔有 28.03% 的佔有率，而次世代定序(NGS) 領域預計將在預測期內實現最快的複合年成長率。
  • 預計非小細胞肺癌領域將在 2024 年佔據市場主導地位，佔有 30.32% 的佔有率，而乳癌領域預計在預測期內實現最快的複合年成長率，達到 9.65%。
  • 2024年，北美佔據了整個神經假體市場的主導地位，市佔率超過40.17%。這得歸功於北美地區神經植入製造商的龐大規模、高額的研發投入以及來自政府和私人機構的資金支持。例如，美國國防高級研究計劃局 (DARPA) 和美國國家神經疾病和中風研究所 (NIH) 與聯邦機構合作，為神經植入的進一步研發提供資金舉措。
  • 由於跨國醫療保健公司進入亞太地區推廣安全有效的醫療程序以及消費者意識層級的提高，亞太地區預計將成為成長最快的地區。
  • 預計在預測期內，策略聯盟和併購將使產業競爭水準保持在高水準。

目錄

第1章 分析方法與範圍

第2章執行摘要

第3章癌症伴隨診斷市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
    • 市場機會
    • 市場挑戰
  • 癌症伴隨診斷市場：分析工具
  • 商業環境分析
    • 產業分析：波特五力分析
    • PESTEL分析

第4章癌症伴隨診斷市場：按產品和服務的估計和趨勢分析

  • 按產品/服務分類的市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 癌症伴隨診斷市場：產品與服務展望
  • 市場規模預測及趨勢分析（2018-2030年）
  • 產品
    • 裝置
    • 耗材
    • 軟體
  • 服務

第5章癌症伴隨診斷市場：按技術分類的估計和趨勢分析

  • 按技術分類的市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 癌症伴隨診斷市場：技術展望
  • 市場規模預測及趨勢分析（2018-2030年）
  • 聚合酵素鏈鎖反應（PCR）
  • 次世代定序（NGS）
  • 免疫組織化學（IHC）
  • 原位雜合反應（ISH）/螢光原位雜合反應（FISH）
  • 其他技術

第6章癌症伴隨診斷市場：依疾病類型估計與趨勢分析

  • 按疾病類型分類的市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 癌症伴隨診斷市場：依疾病類型展望
  • 市場規模預測及趨勢分析（2018-2030年）
  • 乳癌
  • 非小細胞肺癌
  • 大腸直腸癌
  • 白血病
  • 黑色素瘤
  • 攝護腺癌
  • 其他

第7章癌症伴隨診斷市場：依最終用途的估計和趨勢分析

  • 按最終用途分類的市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 癌症伴隨診斷市場：按最終用途分類的展望
  • 市場規模預測及趨勢分析（2018-2030年）
  • 醫院
  • 病理學/診斷實驗室
  • 學術醫療中心

第8章癌症伴隨診斷市場：按地區估計和趨勢分析

  • 各地區市場佔有率分析（2024 年及 2030 年）
  • 區域儀表板
  • 全球市場概況：按地區
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 北美：SWOT分析
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲：SWOT分析
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 亞太地區：SWOT分析
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲：SWOT分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭態勢

  • 主要企業近期趨勢及影響分析
  • 公司分類
  • 公司熱圖分析
  • 公司簡介
    • Agilent Technologies, Inc.
    • Illumina, Inc.
    • QIAGEN
    • Thermo Fisher Scientific Inc.
    • Foundation Medicine, Inc.
    • Myriad Genetics, Inc.
    • F. Hoffmann-La Roche Ltd
    • BIOMERIEUX
    • Abbott
    • Leica Biosystems Nussloch GmbH
    • Guardant Health
    • EntroGen, Inc.
Product Code: GVR-4-68039-049-7

Oncology Companion Diagnostic Market Growth & Trends:

The global oncology companion diagnostic market size is expected to reach USD 8.38 billion by 2030, expanding at a CAGR of 9.02% from 2025 to 2030, according to a new report by Grand View Research, Inc. Expanding access to important genomic information with the aid of companion diagnostics enables informed decision making for designing the targeted treatment approaches for their patients, thereby increasing demand for comprehensive genomic testing and oncology companion diagnostics.

The commercial launch of drugs including Gleevec (imatinib) and Herceptin (trastuzumab) that require Companion Diagnostics (CDx) testing before prescription has increased revenue generation in the oncology companion diagnostics field. This growth is expected to continue in the future owing to a substantial number of CDx associated oncology drugs in clinical trials. Apart from functioning as exclusive or inclusive tests for therapies, CDx also plays a crucial role during participant selection in clinical trials. This is because there is an increased potential for a novel drug candidate to show a better response rate if the patient has its biomarker target.

The economic incentives associated with the use of CDx have encouraged drug developers to combine their drugs with diagnostic tests. However, the diagnostic manufacturers face conflicting demands from payers/providers on one hand and drug manufacturers on the other hand. The regulatory bodies also have stringent policies to align the development timelines of diagnostics and drugs. Therefore, the diagnostic companies are expected to broaden their scope of CDx development instead of focusing on the attainment of a match between a single diagnostic with a specific drug.

Oncology Companion Diagnostic Market Report Highlights:

  • The products segment dominated the market with a share of 66.14% in 2024, driven by advancements in personalized medicine and the increasing prevalence of cancer and the services segment is expected to register the fastest CAGR during the forecast period
  • The Polymerase Chain Reaction (PCR) segment dominated the market with a share of 28.03% in 2024 and the next-generation Sequencing (NGS) segment is expected to register the fastest CAGR during the forecast period
  • The non-small cell lung cancer segment dominated the market, with a share of 30.32% in 2024 and the breast cancer segment is expected to register the fastest CAGR of 9.65% during the forecast period
  • In 2024, North America dominated the overall neuroprosthetics market at over 40.17% owing to the large presence of neural implants manufacturers, higher R&D investments, and the availability of funds from both government and private institutes. For instance, the Defense Advanced Research Project Agency (DARPA) and National Institute of Neurological Disorders and Stroke (NIH)in collaboration with the federal agencies are instrumental in providing funds to support R&D initiatives for the further development of neural implants.
  • Asia Pacific is anticipated to be the fastest growing segment due to the introduction of multinational healthcare establishments promoting safe and effective medical procedures along with the rising awareness levels amongst consumers.
  • Strategic collaborations and mergers & acquisitions are expected to keep the industry rivalry level high over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Oncology Companion Diagnostic Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Oncology Companion Diagnostic Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Oncology Companion Diagnostic Market: Product & Services Estimates & Trend Analysis

  • 4.1. Product and Services Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Oncology Companion Diagnostic Market by Product & Services Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Product
    • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Instrument
      • 4.5.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Consumables
      • 4.5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.4. Software
      • 4.5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Services
    • 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Oncology Companion Diagnostic Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Oncology Companion Diagnostic Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Polymerase Chain Reaction (PCR)
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Next-generation Sequencing (NGS)
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Immunohistochemistry (IHC)
    • 5.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH)
    • 5.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Other Technologies
    • 5.9.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Oncology Companion Diagnostic Market: Disease Type Estimates & Trend Analysis

  • 6.1. Disease Type Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Oncology Companion Diagnostic Market by Disease Type Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Breast Cancer
    • 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Non-small Cell Lung Cancer
    • 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Colorectal Cancer
    • 6.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Leukemia
    • 6.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.9. Melanoma
    • 6.9.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.10. Prostate Cancer
    • 6.10.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.11. Others
    • 6.11.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Oncology Companion Diagnostic Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2024 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Oncology Companion Diagnostic Market by Disease Type Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.5. Hospital
    • 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Pathology/Diagnostic Laboratory
    • 7.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Academic Medical Center
    • 7.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Oncology Companion Diagnostic Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts, Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. North America: SWOT Analysis
    • 8.5.2. U.S.
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.5.3. Canada
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.6. Europe
    • 8.6.1. Europe: SWOT Analysis
    • 8.6.2. UK
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.6.3. Germany
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.6.4. France
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. France market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.6.5. Italy
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.6.6. Spain
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.6.7. Norway
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.6.8. Sweden
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.6.9. Denmark
      • 8.6.9.1. Key country dynamics
      • 8.6.9.2. Regulatory framework
      • 8.6.9.3. Competitive scenario
      • 8.6.9.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Asia Pacific: SWOT Analysis
    • 8.7.2. Japan
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.7.3. China
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. China market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.7.4. India
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. India market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.7.5. Australia
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.7.6. South Korea
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.7.7. Thailand
      • 8.7.7.1. Key country dynamics
      • 8.7.7.2. Regulatory framework
      • 8.7.7.3. Competitive scenario
      • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.8. Latin America
    • 8.8.1. Latin America: SWOT Analysis
    • 8.8.2. Brazil
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.9. MEA
    • 8.9.1. MEA: SWOT Analysis
    • 8.9.2. South Africa
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.9.3. Saudi Arabia
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.9.4. UAE
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.9.5. Kuwait
      • 8.9.5.1. Key country dynamics
      • 8.9.5.2. Regulatory framework
      • 8.9.5.3. Competitive scenario

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. Agilent Technologies, Inc.
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/ Strategic Initiatives
    • 9.4.2. Illumina, Inc.
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/ Strategic Initiatives
    • 9.4.3. QIAGEN
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/ Strategic Initiatives
    • 9.4.4. Thermo Fisher Scientific Inc.
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/ Strategic Initiatives
    • 9.4.5. Foundation Medicine, Inc.
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/ Strategic Initiatives
    • 9.4.6. Myriad Genetics, Inc.
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Recent Developments/ Strategic Initiatives
    • 9.4.7. F. Hoffmann-La Roche Ltd
      • 9.4.7.1. Financial Performance
      • 9.4.7.2. Product Benchmarking
      • 9.4.7.3. Recent Developments/ Strategic Initiatives
    • 9.4.8. BIOMERIEUX
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/ Strategic Initiatives
    • 9.4.9. Abbott
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments/ Strategic Initiatives
    • 9.4.10. Leica Biosystems Nussloch GmbH
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments/ Strategic Initiatives
    • 9.4.11. Guardant Health
      • 9.4.11.1. Participant's Overview
      • 9.4.11.2. Financial Performance
      • 9.4.11.3. Product Benchmarking
      • 9.4.11.4. Recent Developments/ Strategic Initiatives
    • 9.4.12. EntroGen, Inc.
      • 9.4.12.1. Participant's Overview
      • 9.4.12.2. Financial Performance
      • 9.4.12.3. Product Benchmarking
      • 9.4.12.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 4 North America oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 5 North America oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 6 North America oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 7 U.S. oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 8 U.S. oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 9 U.S. oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 10 U.S. oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 12 Canada oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 13 Canada oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 14 Canada oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Mexico oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 16 Mexico oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 17 Mexico oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 18 Mexico oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 20 Europe oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 21 Europe oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 22 Europe oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 23 Europe oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Germany oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 25 Germany oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 26 Germany oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 27 Germany oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 28 UK oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 29 UK oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 30 UK oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 31 UK oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 32 France oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 33 France oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 34 France oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 35 France oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 36 Italy oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 37 Italy oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 38 Italy oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 39 Italy oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Spain oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 41 Spain oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 42 Spain oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 43 Spain oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Denmark oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 45 Denmark oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 46 Denmark oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 47 Denmark oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Sweden oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 49 Sweden oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 50 Sweden oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 51 Sweden oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Norway oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 53 Norway oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 54 Norway oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 55 Norway oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 61 China oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 62 China oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 63 China oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 64 China oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Japan oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 66 Japan oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 67 Japan oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 68 Japan oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 69 India oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 70 India oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 71 India oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 72 India oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 73 South Korea oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 74 South Korea oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 75 South Korea oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 76 South Korea oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 77 Australia oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 78 Australia oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 79 Australia oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 80 Australia oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 81 Thailand oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 82 Thailand oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 83 Thailand oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 84 Thailand oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 85 Latin America oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 86 Latin America oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 87 Latin America oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 88 Latin America oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 89 Brazil oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 90 Brazil oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 91 Brazil oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 92 Brazil oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 93 Argentina oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 94 Argentina oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 95 Argentina oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 96 Argentina oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 97 MEA oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 98 MEA oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 99 MEA oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 100 MEA oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 101 MEA oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 102 South Africa oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 103 South Africa oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 104 South Africa oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 105 South Africa oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 106 Saudi Arabia oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 110 UAE oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 111 UAE oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 112 UAE oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 113 UAE oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 114 Kuwait oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 115 Kuwait oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 116 Kuwait oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 117 Kuwait oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Oncology companion diagnostic market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot-1
  • Fig. 14 Segment snapshot-2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Oncology companion diagnostic market: Product & Services outlook key takeaways
  • Fig. 20 Oncology companion diagnostic market: Product & Services movement analysis
  • Fig. 21 Passive immunization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Preventive vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Oncology companion diagnostic market: Technology outlook key takeaways
  • Fig. 24 Oncology companion diagnostic market: Technology movement analysis
  • Fig. 25 Monoclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Next-generation Sequencing (NGS) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 mRNA-based vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Other Technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Oncology companion diagnostic market: Disease Type outlook key takeaways
  • Fig. 30 Oncology companion diagnostic market: Disease Type movement analysis
  • Fig. 31 Breast Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Non-small Cell Lung Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Colorectal Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Leukemia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Melanoma market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Prostate Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Others estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Oncology companion diagnostic market: End Use outlook key takeaways
  • Fig. 39 Oncology companion diagnostic market: End Use movement analysis
  • Fig. 40 Hospital & retail pharmacies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Government suppliers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Academic Medical Center market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Regional marketplace outlook, 2024 & 2030 (USD million)
  • Fig. 44 Regional marketplace: Key takeaways
  • Fig. 45 North America Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 U.S. Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Canada Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Mexico Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Europe Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 UK Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Germany Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 France Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Spain Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Italy Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Denmark Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Sweden Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Norway Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Asia Pacific Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Japan Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 China Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 India Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Australia Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 South Korea Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Thailand Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Market participant categorization
  • Fig. 84 Oncology companion diagnostic market position analysis, 2024
  • Fig. 85 Strategic framework